ScholarIQanswers from OpenAlex
Boston Scientific Corporation
FunderResearch funding and supported work
Boston Scientific Corporation is a funder indexed in ScholarIQ from OpenAlex.
What is known about Boston Scientific Corporation?
ScholarIQrecord summary
worldwide developer, manufacturer and marketer of medical devices
How many works does Boston Scientific Corporation have?
ScholarIQindexed works
Boston Scientific Corporation has 13,455 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Boston Scientific Corporation?
ScholarIQopenalex
The OpenAlex for Boston Scientific Corporation is on the source record.
What is the ROR of Boston Scientific Corporation?
ScholarIQror
The ROR for Boston Scientific Corporation is on the source record.
What are the most-cited papers on Boston Scientific Corporation?
ScholarIQmost cited works
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
Bertram Pitt, Lars Køber, Piotr Ponikowski, Mihai Gheorghiade, Gerasimos Filippatos, Henry Krum, Christina Nowack, Peter Kolkhof, So Young Kim, Faı̈ez Zannad
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
Gerasimos Filippatos, Stefan D. Anker, Michael Böhm, Mihai Gheorghiade, Lars Køber, Henry Krum, Aldo P. Maggioni, Piotr Ponikowski, Adriaan A. Voors, Faı̈ez Zannad, So Young Kim, Christina Nowack, Giovanni Palombo, Peter Kolkhof, Nina Kimmeskamp‐Kirschbaum, Alexander Pieper, Bertram Pitt
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction
Pardeep S. Jhund, Scott D. Solomon, Kieran F. Docherty, Hiddo J.L. Heerspink, Inder S. Anand, Michael Böhm, Vijay Chopra, Rudolf A. de Boer, Akshay S. Desai, Junbo Ge, Masafumi Kitakaze, Bela Merkley, Eileen O’Meara, Morten Shou, С. Н. Терещенко, Subodh Verma, Pham Nguyễn Vinh, Silvio E. Inzucchi, Lars Køber, Mikhail Kosiborod, Felipe A. Martínez, Piotr Ponikowski, Marc S. Sabatine, Olof Bengtsson, Anna Maria Langkilde, Mikaela Sjöstrand, John J.V. McMurray
The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study
Ewa A. Jankowska, Bridget‐Anne Kirwan, Mikhail Kosiborod, Javed Butler, Stefan D. Anker, Theresa A. McDonagh, Maria Dorobanţu, Jarosław Dróżdż, Gerasimos Filippatos, Andre Keren, Irakli Khintibidze, Hans Kragten, Felipe A. Martínez, Marco Metra, Davor Miličić, José Carlos Nicolau, Marcus Ohlsson, Alexander Parkhomenko, Domingo A. Pascual‐Figal, Frank Ruschitzka, David Sim, Hadi Skouri, Peter van der Meer, Basil S. Lewis, Josep Comín‐Colet, Stephan von Haehling, Alain Cohen‐Solal, Nicolas Danchin, Wolfram Doehner, Henry J. Dargie, Michael Motro, Tim Friede, Vincent Fabien, Fabio Dorigotti, Stuart Pocock, Piotr Ponikowski
Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial
Adrian F. Hernandez, Jacob A. Udell, W. Schuyler Jones, Stefan D. Anker, Mark C. Petrie, Josephine Harrington, Michaela Mattheus, Svenja Seide, Isabella Zwiener, Offer Amir, M. Cecilia Bahit, Johann Bauersachs, Antoni Bayés‐Genís, Yundai Chen, Vijay Chopra, Gemma A. Figtree, Junbo Ge, Shaun G. Goodman, Nina Gotcheva, Shinya Goto, Tomasz Gąsior, Waheed Jamal, James L. Januzzi, Myung Ho Jeong, Yu. M. Lopatin, Renato D. Lópes, Béla Merkely, Puja B. Parikh, Alexander Parkhomenko, Piotr Ponikowski, Xavier Rosselló, Morten Schou, Dragan Šimić, Philippe Gabríel Steg, Joanna Szachniewicz, Peter van der Meer, Dragoş Vinereanu, Shelley Zieroth, Martina Brueckmann, Mikhail Sumin, Deepak L. Bhatt, Javed Butler